Profluent
Designs functional proteins using deep generative AI models.
Company facts
- Founded
- 2022
- Employees
- 51
- Headquarters
- United States
- CEO
- Ali Madani
- Type
- Private
- Funding
- Series B · $106M · 2025
About
Grounded in nature, authored by AI. Proteins are the molecular machines enabling life’s biological functions. The next frontier is authoring new biology, and with AI, we have the power to write the future—creating solutions that transform medicine, agriculture, and beyond. At Profluent, we turn possibilities into reality, one protein at a time. The world’s first AI-designed gene editor, OpenCRISPR, demonstrates authorship in action. Profluent’s AI writes proteins, whether inspired by natural scaffolds or designed from scratch. Our expert team combines machine learning and biology to unlock solutions to complex challenges in protein design. From new therapeutics to industrial enzymes, our AI-authored proteins are revolutionizing how we address challenges across diverse fields.